Vanguard Asset Management
LAB icon

Vanguard Asset Management’s Standard BioTools LAB Stock Holding History

Vanguard Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-131,258
Closed -$121K – 2471
2026
Q1 		$121K Buy
+131,258
New +$159K ﹤0.01% 2410

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's LAB Position: Q2 2026 in Review

Vanguard Asset Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 131,258 shares — an estimated $121K sold.

Vanguard Asset Management first reported a position in LAB in Q1 2026 and held it in 1 quarter. The position peaked at $121K in Q1 2026. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Vanguard Asset Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • Vanguard Asset Management sold 131,258 Standard BioTools shares in Q2 2026, an estimated $121K.
  • Vanguard Asset Management first reported a position in Standard BioTools in Q1 2026 and held it in 1 quarter.
  • Vanguard Asset Management's Standard BioTools position peaked at $121K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.